Letter to the EditorPrevalence of eosinophilic colitis and the diagnoses associated with colonic eosinophilia
References (9)
- et al.
Eosinophilic colitis: case series and literature review
Pathol Res Pract
(2018) - et al.
Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis
Ann Allergy Asthma Immunol
(2018) - et al.
Prevalence of eosinophilic gastroenteritis and colitis in a population-based study, From 2012 to 2017
Clin Gastroenterol Hepatol
(2017) - et al.
Primary colonic eosinophilia and eosinophilic colitis in adults
Am J Surg Pathol
(2017)
Cited by (12)
Non-esophageal eosinophilic gastrointestinal disorders
2022, Human Pathology ReportsCitation Excerpt :Exact prevalence rates remain to be determined, but according to Jensen et al [1], prevalence rates of EoG, EGE and EoC are respectively 6.0, 7.7 and 2.4 per 100,000 persons in general US population, in comparison with 34.4 per 100,000 persons for EoE [2]. Other reports vary with studies dependent on inclusion criteria, population and region [3–6] (Table 1). Non-EoE EGIDs occur in both male and female in any age group.
Prevalence of primary eosinophilic colitis in patients with chronic diarrhea and diarrhea-predominant irritable bowel syndrome
2022, Revista de Gastroenterologia de MexicoEosinophilic gastrointestinal disease below the belt
2020, Journal of Allergy and Clinical ImmunologyOverestimation of the diagnosis of eosinophilic colitis with reliance on billing codes
2019, Journal of Allergy and Clinical Immunology: In PracticeSeasonal variation of eosinophil counts in histologically normal colonic mucosal biopsies
2023, Malaysian Journal of Pathology
Disclosure of potential conflict of interest: P. E. Putnam has received payment for lectures from Abbott Nutrition. V. A. Mukkada reports grants and personal fees from Shire. M. E. Rothenberg is a consultant for PulmOne, Spoon Guru, Celgene, Shire, AstraZeneca, GlaxoSmithKline, Allakos, Adare, Regeneron, and Novartis; has an equity interest in PulmOne, Spoon Guru, Celgene, and Immune Pharmaceuticals; receives royalties from reslizumab (Teva Pharmaceuticals) and UpToDate; and is an inventor of patents owned by Cincinnati Children's Hospital Medical Center. The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to this work.